The FDA grants de novo clearance to HeartFlow's novel system for non-invasive measurement of fractional flow reserve, which CEO Dr. John Stevens calls "the gold standard" for diagnosing and treating coronary disease.
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
Sen. Richard Burr (R-N.C.) introduces a new bill to create fast-track approvals at the FDA for breakthrough medical devices.
A new Senate bill introduced yesterday would create a fast-track program at the FDA for breakthrough medical devices
The bill, S. 1077 or " A bill to provide for expedited development of and priority review for breakthrough devices," was sponsored by Sen. Richard Burr (R-N.C.) and co-sponsored by Sens. Orrin Hatch (R-Utah) and Michael Bennet (D-Colo.).
Share prices tick up for C.R. Bard after it reports a 1st-quarter earnings beat.
C.R. Bard (NYSE:BCR) shares gained today after the medical products giant reported 1st-quarter earnings that topped expectations on Wall Street, despite a poor quarterly comparison for its Lutonix drug-eluting balloon.
Halloran expands clinical finance services and licenses leading industry financial forecasting tool to effectively budget and manage clinical trial budgets.
BOSTON, MA – Halloran Consulting Group, the life science management consulting firm, expands its robust range of clinical finance capabilities with the addition of the industry's leading financial forecasting tool.